Classical swine fever virus non-structural protein 5B hijacks host METTL14-mediated m6A modification to counteract host antiviral immune response.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science, c2005-

Adenine* ; Classical Swine Fever* ; Classical Swine Fever Virus*/genetics; Animals ; Immunity, Innate ; Swine ; Toll-Like Receptor 4

Classical Swine Fever (CSF), caused by the Classical Swine Fever Virus (CSFV), inflicts significant economic losses on the global pig industry. A key factor in the challenge of eradicating this virus is its ability to evade the host's innate immune response, leading to persistent infections. In our study, we elucidate the molecular mechanism through which CSFV exploits m6A modifications to circumvent host immune surveillance, thus facilitating its proliferation. We initially discovered that m6A modifications were elevated both in vivo and in vitro upon CSFV infection, particularly noting an increase in the expression of the methyltransferase METTL14. CSFV non-structural protein 5B was found to hijack HRD1, the E3 ubiquitin ligase for METTL14, preventing METTL14 degradation. MeRIP-seq analysis further revealed that METTL14 specifically targeted and methylated TLRs, notably TLR4. METTL14-mediated regulation of TLR4 degradation, facilitated by YTHDF2, led to the accelerated mRNA decay of TLR4. Consequently, TLR4-mediated NF-κB signaling, a crucial component of the innate immune response, is suppressed by CSFV. Collectively, these data effectively highlight the viral evasion tactics, shedding light on potential antiviral strategies targeting METTL14 to curb CSFV infection.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Viruses. 2022 Aug 18;14(8):. (PMID: 36016430)
Sci Rep. 2016 May 23;6:26350. (PMID: 27211830)
Nucleic Acids Res. 2019 Jan 10;47(1):362-374. (PMID: 30364964)
Science. 2019 Sep 13;365(6458):1171-1176. (PMID: 31439758)
J Virol. 1978 Oct;28(1):75-83. (PMID: 702657)
Antiviral Res. 2014 Apr;104:128-35. (PMID: 24500530)
Mol Cell. 2021 Dec 16;81(24):5052-5065.e6. (PMID: 34847358)
PLoS Pathog. 2016 Aug 30;12(8):e1005841. (PMID: 27575636)
Nature. 2012 Apr 29;485(7397):201-6. (PMID: 22575960)
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):. (PMID: 34282019)
PLoS Pathog. 2018 Sep 17;14(9):e1007290. (PMID: 30222771)
Science. 2003 Aug 1;301(5633):640-3. (PMID: 12855817)
PLoS Negl Trop Dis. 2007 Nov 21;1(2):e86. (PMID: 18060089)
Mol Cell. 2016 Jul 21;63(2):306-317. (PMID: 27373337)
PLoS Negl Trop Dis. 2013;7(3):e2107. (PMID: 23516652)
Apoptosis. 2022 Jun;27(5-6):426-440. (PMID: 35503144)
Virulence. 2023 Dec;14(1):2232910. (PMID: 37418592)
Science. 2016 Jun 17;352(6292):1408-12. (PMID: 27313037)
BMC Vet Res. 2015 Oct 15;11:264. (PMID: 26472464)
Vet Microbiol. 2010 Apr 21;142(1-2):51-8. (PMID: 19896784)
Front Microbiol. 2023 Feb 03;14:1087484. (PMID: 36819040)
Front Immunol. 2012 Apr 18;3:79. (PMID: 22566960)
Microbiol Spectr. 2022 Jun 29;10(3):e0109822. (PMID: 35583334)
Elife. 2017 Oct 06;6:. (PMID: 28984244)
J Gen Virol. 2017 Jan;98(1):2-3. (PMID: 28218572)
PLoS Pathog. 2019 Jun 21;15(6):e1007796. (PMID: 31226160)
Macromol Biosci. 2021 Apr;21(4):e2000382. (PMID: 33522144)
Nat Commun. 2016 Aug 25;7:12626. (PMID: 27558897)
J Virol. 2016 Nov 14;90(23):10472-10485. (PMID: 27630238)
Elife. 2018 Feb 16;7:. (PMID: 29451494)
J Exp Med. 2003 Oct 6;198(7):1043-55. (PMID: 14517278)
Nat Microbiol. 2020 Apr;5(4):584-598. (PMID: 32015498)
J Gen Virol. 2001 Jun;82(Pt 6):1309-1318. (PMID: 11369874)
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):2916-21. (PMID: 26929335)
Wiley Interdiscip Rev RNA. 2022 Nov;13(6):e1725. (PMID: 35301791)
ACS Omega. 2021 Jun 11;6(24):15957-15963. (PMID: 34179640)
Immunity. 2011 May 27;34(5):637-50. (PMID: 21616434)
Virol J. 2012 Nov 27;9:293. (PMID: 23186553)
Cell. 2015 Sep 10;162(6):1299-308. (PMID: 26321680)
Vet Microbiol. 2000 Apr 13;73(2-3):93-102. (PMID: 10785320)
J Virol. 2022 Nov 23;96(22):e0099722. (PMID: 36314819)
J Virol. 1998 Mar;72(3):1853-61. (PMID: 9499036)
Nat Immunol. 2019 Feb;20(2):173-182. (PMID: 30559377)
J Mol Biol. 2014 Mar 20;426(6):1246-64. (PMID: 24316048)
J Gen Virol. 2010 Apr;91(Pt 4):1038-46. (PMID: 20007358)
Cell. 2012 Jun 22;149(7):1635-46. (PMID: 22608085)
Virus Res. 2010 Mar;148(1-2):60-70. (PMID: 20034523)
J Virol. 2022 Oct 12;96(19):e0112422. (PMID: 36102650)
Curr Biol. 2011 Jul 12;21(13):R488-93. (PMID: 21741580)
Vet Microbiol. 2019 Mar;230:101-109. (PMID: 30827374)
Wiley Interdiscip Rev RNA. 2023 Sep 6;:e1810. (PMID: 37674370)
Elife. 2016 Sep 14;5:. (PMID: 27627798)
J Virol. 2010 Feb;84(3):1536-49. (PMID: 19923180)
Cell Rep. 2023 Mar 28;42(3):112259. (PMID: 36920907)
Vet Microbiol. 2000 Jul 3;75(1):1-9. (PMID: 10865147)
Vet Microbiol. 2012 Oct 12;159(3-4):327-36. (PMID: 22608103)
Viruses. 2017 May 26;9(6):. (PMID: 28587150)
Virus Res. 2010 Jul;151(1):10-8. (PMID: 20302897)
Arch Virol. 2013 Feb;158(2):325-39. (PMID: 23053521)
Mol Cell. 2016 May 5;62(3):335-345. (PMID: 27117702)
Immunity. 1999 Jul;11(1):115-22. (PMID: 10435584)
Annu Rev Cell Dev Biol. 2017 Oct 6;33:319-342. (PMID: 28759256)
Vet Immunol Immunopathol. 2001 Jan 10;78(1):3-19. (PMID: 11182144)

0 (6-methyladenine)
JAC85A2161 (Adenine)
0 (Toll-Like Receptor 4)

Date Created: 20240329 Date Completed: 20240412 Latest Revision: 20240425

20240426

PMC11006178

10.1371/journal.ppat.1012130

38551978